Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309959 · ClinicalTrials.gov registry record · Phase 2
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase 2 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 20
- Study locations
NCT00309959 is a Phase 2 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 37 participants, below the 120-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00309959, a Phase 2 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Study Locations (20)
Iowa
- Iowa Methodist Medical Center - Des Moines
- Iowa Oncology Research Association CCOP - Des Moines
- Medical Oncology and Hematology Associates-Des Moines - Des Moines
- Medical Oncology and Hematology Associates-Laurel - Des Moines
- Mercy Medical Center - Des Moines - Des Moines
- Iowa Lutheran Hospital - Des Moines
New Jersey
- Cooper Hospital University Medical Center - Camden
- Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County - Mount Holly
- Virtua West Jersey Hospital Voorhees - Voorhees Township
Illinois
- Rush University Medical Center - Chicago
- Carle Clinic-Urbana Main - Urbana
Ohio
- Cleveland Clinic Foundation - Cleveland
- Lake University Ireland Cancer Center - Mentor
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
- Tulsa Cancer Institute - Tulsa
Colorado
- University of Colorado Cancer Center - Anschutz Cancer Pavilion - Aurora
Missouri
- Mercy Hospital Springfield - Springfield
Nevada
- Women's Cancer Center of Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309959
The ClinicalTrials.gov registry entry for NCT00309959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (69% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cervical Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00309959 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Iowa, New Jersey, Illinois.
Frequently Asked Questions
What is clinical trial NCT00309959 about?
NCT00309959 is a clinical study titled "ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer". This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
What is the current status of trial NCT00309959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2006-11.
What conditions does trial NCT00309959 study?
This clinical trial studies the following conditions: Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Cervical Small Cell Carcinoma.
What interventions are being tested in trial NCT00309959?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG).
Who is sponsoring clinical trial NCT00309959?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00309959 being conducted?
This trial has 20 study locations across Colorado, Illinois, Iowa, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
COMPLETED · Phase 2
-
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
COMPLETED · Phase 2
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.